According to GW Pharmaceuticals, European marketing partner Almirall S.A. (Madrid:ALM, Barcelona, Spain) said the price in Germany for Sativex to treat spasticity due to multiple sclerosis is "unacceptable." An independent arbitration board determined the price...
According to GW Pharmaceuticals plc (LSE:GWP), European marketing partner Almirall S.A. (Madrid:ALM) said the price in Germany for Sativex to treat spasticity due to multiple sclerosis (MS) is "unacceptable." An independent arbitration board determined the...
Germany's Federal Joint Committee (G-BA) said Sativex from GW Pharmaceuticals provides a "marginal" degree of additional benefit over optimized standard therapy to treat spasticity in multiple sclerosis (MS) patients. In April, the Institute for Quality...
Germany's Federal Joint Committee (G-BA) said Sativex from GW Pharmaceuticals plc (LSE:GWP) provides a "marginal" degree of additional benefit over optimized standard therapy to treat spasticity in multiple sclerosis (MS) patients. In April, the Institute...
The German Institute for Quality and Efficiency in Health Care (IQWiG) issued a preliminary benefit assessment that assigned Sativex from GW Pharmaceuticals a rating of "no additional benefit" for the indication of treating spasticity in...
The German Institute for Quality and Efficiency in Health Care (IQWiG) issued a preliminary benefit assessment that assigned Sativex from GW Pharmaceuticals plc (LSE:GWP) a rating of "no additional benefit" for the indication of treating...
...Watson Pharma Inc. subsidiary launched in the U.S. an authorized generic of spasticity drug Zanaflextizanidine... ...drug from Elan Corp. plc (NYSE:ELN, Dublin, Ireland) under a 2004 deal. Net revenue of Zanaflex...
